Tests an exoskeleton to help walking recovery after a recent stroke
Tests the Atalante walking exoskeleton alongside therapy in adults with stroke-related leg weakness.
Plain-language title generated from the registry record
Registry title: Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Institut GuttmannBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wandercraft
- Trial code
- NCT06107010
- Record updated
- 4 February 2025
- Original description
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.Read full original descriptionShow less
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
This clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group.
The duration of the intervention period in both groups is 6 weeks.
* For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy. * For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).
The study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.
Inclusion: >18 years old; First clinically significant disability due to stroke; Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke; Functional Ambulation Category score (FAC) <2; Patient with health insurance; Informed and willing to sign an informed consent form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he/she can still be included if the signature can be done by an impartial witness.
Exclusion: Recent fracture (< 3 months) or any therapy inducing secondary osteoporosis; Concurrent participation in another interventional trial; Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA; Uncontrolled seizures; Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion; Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion; Medical contra-indication to medium intensity physical strain; Orthostatic hypotension (loss of > 20 mmHg systolic BP after 3 minutes in standing position); Morphological contra-indications to the use of Atalante (as per user's manual); Pregnant woman; Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention.